In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 10, 2014, Pages 2873-2875

  Marrs, Emma C L ^a   Day, Kathryn M ^a   Perry, John D ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial susceptibility; Urinary tract infections; lactamases

Indexed keywords

BETA LACTAMASE AMPC; BETA LACTAMASE TEM 1; CARBAPENEMASE; CLAVULANATE POTASSIUM; MECILLINAM; PIVMECILLINAM; PROTEIN NDM 1; UNCLASSIFIED DRUG; BETA LACTAMASE;

ANTIBIOTIC SENSITIVITY; BACTERIURIA; DRUG EFFICACY; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FECES ANALYSIS; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LETTER; MIC50; MIC90; NONHUMAN; SCREENING; URINARY TRACT INFECTION; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; FEMALE; KLEBSIELLA INFECTIONS; MALE; SECRETION (PROCESS); URINARY TRACT INFECTIONS;

AMDINOCILLIN PIVOXIL; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; URINARY TRACT INFECTIONS;

EID: 84937694499     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku204     Document Type: Letter

References (9)

1. Jansåker F, Frimodt-Møller N, Sjögren I et al. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014; 69: 769-72.
2. Thomas K, Weinbren MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006; 57: 367-8.
3. Lampri N, Galani I, Poulakou G et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2012; 67: 2424-8.
4. CDC. Detection of Enterobacteriaceae isolates carrying metallo-blactamase-United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 750.
5. Perry JD, Naqvi SH, Mirza IA et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011; 66: 2288-94.
6. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
7. Titelman E, Iversen A, Kalin M et al. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012; 18: 189-92.
8. Søraas A, Sundsfjord A, Jørgensen SB et al. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One 2014; 9: e85889.
9. Jain A, Hopkins KL, Turton J et al. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. J Antimicrob Chemother 2014; 69: 1777-84.